The Food and Drug Administration granted orphan drug designation to PhaseRx Inc. (Nasdaq: PZRX) for its ornithine transcarbamylase deficiency treatment PRX-OTC. Shares of the biopharmaceutical more than doubled by leaping $1.69 to close at $2.82.